Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia | BioSpace
Keeping up with the clinical advances: depression | CNS Spectrums | Cambridge Core
sage-10k_20161231.htm
Sage shares up after FDA allows expedited depression drug development
sage-10k_20161231.htm
Sage Therapeutics Reports Positive Top-Line Results from Phase II Placebo-Controlled Trial of SAGE-217 in MDD - Drug Discovery and Development
Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
Sage Therapeutics Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder Does Not Meet
Schematic model for the initial cellular target sites of rapid-acting... | Download Scientific Diagram
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration | Sage Therapeutics, Inc.
Sage surges after depression drug gets rapid path to approval - PMLiVE
Bait and Switch: the Great Ketamine “Breakthrough” | RxISK
sage-10k_20181231.htm
Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression | BioSpace
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Breakthrough Agitation Agent; Demi Lovato's Bipolar Misdiagnosis? | MedPage Today
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder - Chemdiv
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress | Business Wire
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
